[HTML][HTML] Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience
L Staudacher, PH Cottu, V Dieras, A Vincent-Salomon… - Annals of oncology, 2011 - Elsevier
L Staudacher, PH Cottu, V Dieras, A Vincent-Salomon, MN Guilhaume, L Escalup, T Dorval…
Annals of oncology, 2011•ElsevierBackground Although recent experimental data strongly suggest that platinum-based
chemotherapy (PBCT) could improve the outcome of triple-negative breast cancer (TNBC),
clinical data are lacking. Here, the authors reviewed clinical outcome in patients with
metastatic TNBC treated with PBCT. Patients and methods We conducted a retrospective
analysis of all patients (N= 143) treated for metastatic breast cancer with PBCT between
2000 and 2008, at Institut Curie, Paris, France. Ninety-three of them (63.7%) had TNBC. One …
chemotherapy (PBCT) could improve the outcome of triple-negative breast cancer (TNBC),
clinical data are lacking. Here, the authors reviewed clinical outcome in patients with
metastatic TNBC treated with PBCT. Patients and methods We conducted a retrospective
analysis of all patients (N= 143) treated for metastatic breast cancer with PBCT between
2000 and 2008, at Institut Curie, Paris, France. Ninety-three of them (63.7%) had TNBC. One …
Background
Although recent experimental data strongly suggest that platinum-based chemotherapy (PBCT) could improve the outcome of triple-negative breast cancer (TNBC), clinical data are lacking. Here, the authors reviewed clinical outcome in patients with metastatic TNBC treated with PBCT.
Patients and methods
We conducted a retrospective analysis of all patients (N = 143) treated for metastatic breast cancer with PBCT between 2000 and 2008, at Institut Curie, Paris, France. Ninety-three of them (63.7%) had TNBC. One-hundred twenty patients received cisplatin (CDDP). The main combination used was CDDP–ifosfamide, in 101 patients (70.2%).
Results
Median follow-up was 44 months. For the overall population (N = 143), median overall survival (OS) and median progression-free survival (PFS) were 11 and 5 months, respectively. Objective response rate was 33.3% in the TNBC group versus 22% in non-TNBC, P = 0.1. We observed no difference of OS, PFS and response duration. Other prognostic factors for poor OS were visceral metastasis sites (P < 0.001). One patient died from sepsis during aplasia, 15 had to switch from CDDP to carboplatin because of CDDP-related toxicity.
Conclusions
Metastatic TNBC patients treated with PBCT tended to have a higher response rate, without a significant improvement of PFS or OS, compared with other subtypes. Toxicity was acceptable. Longer observation and further analysis are warranted.
Elsevier